Overview
Most metabolic-research compounds in this catalog are incretin-system agonists (GLP-1, GIP, and glucagon-receptor ligands) and related signaling molecules. The published literature studies them for metabolic and body-composition research endpoints. This guide describes how the compound is characterized and what that research covers. It is not usage guidance and makes no claim about outcomes from use.
A C-terminal fragment analog of human growth hormone studied for effects on lipid metabolism without the full GH sequence.
Evidence at a glance: Preclinical (animal) evidence
The cited evidence here is preclinical animal-model work, with limited or no human-trial data. Read the research profile accordingly.
Molecular identity
- Molecular formula
- C78H123N23O23S2
- Molecular weight
- 1815.1 g/mol
- CAS number
- 221231-10-3
- Amino acids
- 16
- Appearance
- White lyophilized powder
- Purity (HPLC)
- 99%
Researched mechanism
Fragment of the GH 176-191 region studied for lipolytic signaling in research models, without affecting IGF-1 pathways.
Described as a mechanism characterized in the literature, not an effect you should expect from use.
What the published research shows
Lipolytic activity examined in preclinical and early human research.
Honest note on evidence: Human evidence is limited; most data is preclinical.
Every citation states its study type and population, so preclinical data is never presented as human-efficacy evidence.
How it compares
| Versus | Attribute | Note |
|---|---|---|
| Tesamorelin | Mechanism | Tesamorelin acts via GHRH; AOD-9604 is a GH fragment analog. |
Reconstitution
Concentration math only: adding bacteriostatic water to the vial gives the resulting mg/mL shown below. This is not usage guidance.
| Vial | Bacteriostatic water | Concentration |
|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL |
Storage & stability
| State | Temperature | Duration |
|---|---|---|
| Lyophilized (unopened) | -20°C | 24 months |
| Reconstituted | 2–8°C | up to 4 weeks |
Common questions
Does it raise IGF-1?+
Published research describes it as acting on lipid pathways without the IGF-1 effects of full GH. See cited sources.
